文献速递精神分裂症与精神病性障碍

通过精神分裂症相关基因网络重新审视抗精神病药作用

Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia.
PubMed 文献 · Am J Psychiatry · 2018-03-02

研究利用蛋白相互作用组将88个抗精神病药靶点映射至328个精神分裂症风险基因网络,发现风险基因在相互作用组中显著聚集形成疾病模块,其核心基因富集于发育生物学与认知相关基因。抗精神病药靶点与核心疾病模块重叠并涵盖多巴胺以外通路,部分风险基因未连接现有药物但可能成为新药或药物重定位靶点。

要点

  • 精神分裂症风险基因在蛋白相互作用组中显著聚集形成独特疾病模块。
  • 抗精神病药靶点与疾病模块核心重叠,涉及多巴胺以外多条通路。
  • CHRN、PCDH、HCN家族等风险基因未连接现有抗精神病药,或为认知/阴性症状新靶点。

核心结论

  • 网络医学方法可整合疾病遗传学与药物-基因相互作用信息,推动从开发抗精神病药转向多靶点抗精神分裂症药物。

研究设计与样本

  • 研究利用蛋白相互作用组将88个抗精神病药靶点映射至328个精神分裂症风险基因网络。

主要发现

  • 精神分裂症风险基因在相互作用组中显著定位,形成独特疾病模块。
  • 疾病模块核心基因富集于发育生物学与认知相关基因,可能在对精神分裂症病因学中起核心作用。
  • 抗精神病药靶点与核心疾病模块重叠,涵盖多巴胺以外多条通路。
  • CHRN、PCDH、HCN家族等重要风险基因未连接现有抗精神病药,可能适合作为新药或药物重定位靶点以治疗认知或阴性症状。

临床怎么用

  • 网络医学方法可整合疾病遗传学与药物-基因相互作用信息,辅助识别多靶点抗精神分裂症药物研发方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Antipsychotic drugs were incidentally discovered in the 1950s, but their mechanisms of action are still not understood. Better understanding of schizophrenia pathogenesis could shed light on actions of current drugs and reveal novel "druggable" pathways for unmet therapeutic needs. Recent genome-wide association studies offer unprecedented opportunities to characterize disease gene networks and uncover drug-disease relationships. Polygenic overlap between schizophrenia risk genes and antipsychotic drug targets has been demonstrated, but specific genes and pathways constituting this overlap are undetermined. Risk genes of polygenic disorders do not operate in isolation but in combination with other genes through protein-protein interactions among gene product. METHOD: The protein interactome was used to map antipsychotic drug targets (N=88) to networks of schizophrenia risk genes (N=328). RESULTS: Schizophrenia risk genes were significantly localized in the interactome, forming a distinct disease module. Core genes of the module were enriched for genes involved in developmental biology and cognition, which may have a central role in schizophrenia etiology. Antipsychotic drug targets overlapped with the core disease module and comprised multiple pathways beyond dopamine. Some important risk genes like CHRN, PCDH, and HCN families were not connected to existing antipsychotics but may be suitable targets for novel drugs or drug repurposing opportunities to treat other aspects of schizophrenia, such as cognitive or negative symptoms. CONCLUSIONS: The network medicine approach provides a platform to collate information of disease genetics and drug-gene interactions to shift focus from development of antipsychotics to multitarget antischizophrenia drugs. This approach is transferable to other diseases.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kauppi K, Rosenthal SB, Lo MT, et al. Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia. Am J Psychiatry. 2018. PMID: 29495895. doi:10.1176/appi.ajp.2017.17040410

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。